风险应对与行业信心维护 针对投资者担忧的应收账款、银行贷款、库存等风险，公司称将通过优化经营策略，专业、合规推广促 进销售来化解。对于行业内疫苗真假疑虑导致接种意愿下降的问题，公司强调国家对疫苗实行最严格管 理制度，公司也将以优质产品服务民众健康需求。 9月25日，重庆智飞生物制品股份有限公司在全景网"投资者关系互动平台"举行线上路演活动，参与此 次重庆辖区上市公司2025年投资者网上集体接待日暨半年度业绩说明会的投资者与公司管理层进行了深 入交流。公司董事、副总裁、董事会秘书秦菲，以及公司董事、副总裁、财务总监李振敬出席会议，就 公司经营、产品研发、市场策略等投资者关心的问题进行解答。 业绩承压，积极应对转型挑战 投资者关注到公司今年连续两个季度亏损严重，对此公司表示持续优化经营策略，深耕主业，推动"预 防&治疗"协同发展，加速自研产品上市，以实现平稳发展。在产品布局方面，公司共有15种产品上 市，其中1种附条件上市，涵盖多种传染病疫苗及结核相关诊断、预防和治疗产品。 关于市场关心的三季度业绩，公司回应称经营业绩及财务数据请关注定期报告。公司已建立三大研产基 地及一个创新孵化中心，在疫苗、结核类生物制品及G ...

Group 1 - The major shareholder Yuan Liping of Kangtai Biological plans to reduce her stake by no more than 1% of the company's total shares, which amounts to a maximum of 11,160,000 shares [1] - Yuan Liping directly holds 18.06% of the company's shares and indirectly holds 4.05% through other entities [1] - The company has faced significant performance declines in 2024, with revenue dropping by 23.75% to 2.652 billion yuan and net profit decreasing by 76.6% to 202 million yuan [2] Group 2 - In the first quarter of 2025, the company reported a revenue of 645 million yuan, a year-on-year increase of 42.85%, but the net profit attributable to the parent company fell by 58.51% to 22.43 million yuan [2] - The company’s accounts receivable at the end of 2024 stood at 2.787 billion yuan, representing 19.14% of total assets, and increased to 2.854 billion yuan by the end of the first quarter of 2025 [3] - Kangtai Biological is expanding its product pipeline to include vaccines for adults and is actively seeking to enter international markets, particularly in emerging markets and developing countries [3]